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 47 
What’s already known about this topic? 48 
• Iatrogenic PPROM is a major risk factor of fetoscopic procedures 49 
• So far used sealants are not efficient to prevent iPPROM 50 
• Further research is needed 51 
 52 
 53 
What does this study add? 54 
• We screened five sealants for biocompatibility and efficacy to seal fetal membrane defects 55 
• Tissuepatch® was biocompatible and had a good efficacy 56 
• Tissuepatch® could be used in open fetal surgery to prevent iPPROM 57 
 58 
59 
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Abstract 60 
 61 
Objective: To evaluate novel sealing techniques for their biocompatibility and sealing capacity of 62 
iatrogenic fetal membrane defects in a pregnant rabbit model. 63 
Method: At day 23 of gestation (term=d31), a standardized fetoscopy was performed through a 14G 64 
cannula. The resulting fetal membrane defect was closed with either condensed collagen, collagen 65 
with fibrinogen, Tissuepatch®, Duraseal®, or a conventional collagen plug (Lyostypt®) as reference. At 66 
d30 the fetuses were harvested and full thickness fetal membrane samples were analyzed. The study 67 
consisted of two consecutive parts: (1) biocompatibility testing by fetal survival, apoptosis and 68 
infiltration of polymorphonuclear cells in the membranes; (2) the efficacy to seal fetal membrane 69 
defects. 70 
Results: Three sealants (collagen with fib inogen, Duraseal® or Lyostypt®) were associated with a 71 
higher fetal mortality compared to control unmanipulated littermates, and hence were excluded 72 
from further analysis. Tissuepatch® was biocompatible and amniotic fluid levels were comparable to 73 
those of control untouched littermates. Compared to the condensed collagen, Tissuepatch® was also 74 
easier in surgical handling and induced limited cell proliferation. 75 
Conclusion: Tissuepatch® had the best biocompatibility and efficacy in sealing an iatrogenic fetal 76 
membrane defect in the pregnant rabbit compared to other readily available sealants.  77 
 78 
 79 
80 
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Introduction 81 
 82 
Fetal membrane rupture remains the Achilles’ heel of fetal surgery, occurring in around 28% of laser 83 
interventions for twin-twin transfusion syndrome (TTTS) and around 47% of fetoscopic endoluminal 84 
tracheal occlusion (FETO) for congenital diaphragmatic hernia (CDH) 
1,2
. Therefore, several strategies 85 
to either treat or prevent membrane rupture have been proposed 
3–6
. 86 
Primary prevention of preterm premature rupture of membranes (PPROM) at the time of fetal 87 
surgery would be a useful approach. To our knowledge, only collagen and gelatin plugs have been 88 
used clinically for this purpose, however with contradicting results 
7–9
. Clinical studies on potential 89 
new solutions are difficult to perform as “first-in-man” studies in pregnancy are challenging, using 90 
products that are or would be used off label. It is important to analyze the healing site histologically, 91 
and to set up a controlled study which is adequately powered. In vivo animal studies are hence vital 92 
to allow researchers to explore new solutions. The optimal candidate surgical solution to us, should 93 
ideally have the following features: (1) the device or material should be readily available and (2) 94 
clinically applicable through a 10 Fr, preferentially also an 8 Fr cannula, either as is or after 95 
modification. (3) The material should have the ability to be bio-activated and/or (4) to function as a 96 
transport of molecular therapeutics to interfere with, apart from the defect, other potential 97 
biomolecular mechanism behind iatrogenic PPROM (iPPROM)
10
.” 98 
Herein we report on four novel sealant techniques which we compared to the conventional collagen 99 
plugs (Lyostypt®) as a reference sealant in the study. One sealant is a condensed collagen, which has 100 
been tissue engineered from human fetal membranes and which demonstrated good growth-101 
support of amnion epithelial cells 
11
. The second sealant is an off-the-shelf collagen (Lyostypt®) 102 
imbued with fibrinogen. This was tested before in vitro in human amniotic membranes and showed 103 
improved sealing capabilities 
12
. The third sealant is Tissuepatch® which is a thin film and clinically is 104 
used to obtain an airtight sealant in thoracoscopic surgeries. The fourth sealant is Duraseal®, which is 105 
used in neurosurgery for sealing dura mater defects and preventing cerebrospinal fluid leakage 
13
. 106 
We tested those sealants in vivo for their biocompatibility (safety) and their efficacy to seal a fetal 107 
membrane defect in a pregnant rabbit model for fetoscopy.  108 
109 
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Material and Methods 110 
 111 
Study design 112 
 113 
The study design is shown in Supplementary Figure 1. Pregnant rabbits underwent a laparotomy at 114 
23 days of gestation under general anaesthesia, three fetuses out of the total litter were operated on 115 
and assigned to one of 5 types of fetal membrane sealant or positive control (no sealant); the 116 
remaining fetuses acted as negative unoperated controls. One week later, pregnancies were 117 
evaluated for fetal survival, the primary outcome variable of the biocompatibility testing. Secondary 118 
outcomes were inflammation and apoptosis. Sealants performing best in the primary outcome 119 
measure were further tested for efficacy, i.e. by the deepest vertical pocket (DVP) on ultrasound at 120 
term. Further secondary outcomes were ease of surgical handling at the time of sealant insertion, 121 
and what were considered as additional efficacy outcome measures such as amniotic fluid leakage, 122 
persistence of the plug, Ki67 positive cells and the ratio of vimentin and cytokeratin as a marker for 123 
epithelial-mesenchymal transition (EMT). The lung-to-bodyweight ratio (LBWR) of the fetus was 124 
quantified as a further efficacy measure to assess pulmonary hypoplasia. 125 
Animal and surgical protocols 126 
 127 
This experiment was approved by the local Ethics committee of KU Leuven (P250/2014) and animals 128 
were handled according to the current guidelines on animal welfare. Time mated pregnant does 129 
(hybrid of New Zealand and Dendermonde) were housed at the animalium of the group Biomedical 130 
Sciences in separate cages on a 12-hour light cycle with free access to food and water. At 23 days of 131 
gestational age (GA; term = 31 days) the doe was sedated with intramuscular ketamine 35 mg/kg 132 
bodyweight (BW) (Ketamine 1000 CEVA; CEVA Santé Animal, Brussels, Belgium) and xylazin 6 mg/kg 133 
BW (Vexylan®; CEVA Santé Animal). Buprenorphine 0.03 mg/kg (Vetergesic®; Reckitt Benckiser 134 
Healthcare, Brussels, Belgium), medroxyprogesterone acetate (Depo-Provera, Pfizer, Puurs, Belgium) 135 
and penicillin G (Kela Pharma, Hoogstraten, Belgium) were injected subcutaneously. General 136 
anesthesia was maintained using isoflurane 1.5% (Isoba®
 
Vet; Abbott Laboratories Ltd., 137 
Queensborough, Kent, UK) in oxygen at 2 L/minute via a facemask. Maternal vital parameters were 138 
monitored with a pulse oxymeter (Nellcor®
 
N- 20P; Nellcor Inc., Haasrode, Belgium). Physiologic body 139 
temperature was maintained by a heating pad.  140 
The doe was placed in the supine position, the abdomen was shaved and disinfected with povidone 141 
iodine (Isobetadine®; Asta Medica, Brussels, Belgium) and covered with sterile drapes. After midline 142 
laparotomy, the uterus was exposed and the fetal sacs counted. We operated on three fetuses in 143 
each litter, i.e. both ovarian end fetuses and one more in the horn with the highest number of 144 
fetuses, leaving one unoperated fetus in between. In case of equal numbers of fetuses in both horns, 145 
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a random side was chosen. First a small myometrial incision of 3-4 mm was made on the anti-146 
mesometrial side. Blunt dissection of the chorion was performed to gain access to the amnion and to 147 
avoid damage to the vitelline vessels (Figure 1A). After exposure of the amniotic membrane, it was 148 
punctured with a 14 G Cannula (Braun Medical N.V., Diegem, Belgium) at a perpendicular angle and a 149 
standardized diagnostic fetoscopy of fixed duration (2 min) was performed with a 1.0 mm 150 
embryoscope (11510A, Karl Storz, Tutlingen, Germany) within a 1.3 mm examination sheath 151 
(11510KA, Karl Storz) (Supplementary Video 1, Figure 1B), as previously described 
14
. By using this 152 
type of diameter instruments, the defect was large enough (around 1.3 mm) to surgically introduce 153 
the sealant.  154 
The gestational sacs were randomly assigned to one of the following treatment groups: (1) Lyostypt® 155 
(B. Braun Medical N.V.), (2) Lyostypt® soaked in fibrinogen concentrate (Haemocomplettan®, CSL 156 
Behring, Breda, The Netherlands), (3) condensed collagen, (4) Tissuepatch® (Tissuemed Ltd, Leeds, 157 
United Kingdom), (5) Duraseal® (Integra LS N.V., Zaventem, Belgium) or (6) positive controls (SHAM 158 
surgery without sealant). The sealant was positioned in or over the amnion defect. The collagen 159 
sealants were fixed within the defect by a single stitch 6-0 Prolene to the fetal membranes and the 160 
myometrium (Ethicon, Johnson & Johnson Medical N.V., Diegem, Belgium). Tissuepatch® was fixed 161 
on the inside of the amniotic cavity with its self-adhesive side to the amnion epithelium with two 6-0 162 
Prolene sutures to the fetal membranes and the myometrium. Duraseal® was sprayed upon the 163 
amniotic defect. Any problem with proper placement of the plug, or any discordant opinion on 164 
appropriate plug positioning by the surgeons (ACE and LJ) were categorized as problematic. The 165 
unoperated gestation sacs were used as negative controls. The myometrium was closed with 3 single 166 
stitches with 6-0 Prolene suture (Figure 1D). The doe’s abdominal wall was closed in two layers with 167 
2-0 Vicryl (Ethicon) for the muscular layer and 3-0 Ethilon (Ethicon) for the intracutaneous skin 168 
suture.  169 
At 30 days GA, the does were premedicated and anesthetized as above. Micro-ultrasound (Vevo® 170 
2100 System, Visual Sonics, Toronto) was used to assess the deepest vertical pocket (DVP) and 171 
determine fetal survival. After that, macroscopic amniotic fluid leakage at the operated area was 172 
evaluated with blotting paper (3x1 cm, 125 g/m
2
, Aurora Productions SA, Turnhout, Belgium) for 10 173 
seconds after drying the area with surgical gauze. Thereafter the does and fetuses were euthanized 174 
with an intravenous bolus of a mixture of embutramide 200 mg, mebezonium 50 mg, and tetracaine 175 
hydrochloride 5 mg (0,3 mL/kg T61; Marion Roussel Hoechst, Brussels, Belgium) and samples were 176 
obtained.  177 
Harvesting and sample preparation 178 
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We identified the entry point to the fetal sac by the marking suture and pre-elevated it “en bloc” 179 
(amnion, chorion and myometrium; further referred to as FM sample). Persistence or absence of the 180 
plug in the myometrium and/or the fetal membranes was macroscopically assessed from the inside 181 
of the amniotic cavity. FM samples of surviving fetuses were stored in tissue embedding cassettes 182 
(Simport, Beloeil, Quebec, Canada) on foam biopsy pads (Leica Biosystems N.V., Maarn, The 183 
Netherlands) and submerged in 4% buffered paraformaldehyde (PFA) (Klinipath BV, Duiven, The 184 
Netherlands) for 24 hours. They were then transferred to 70% ethanol and embedded in paraffin. At 185 
necropsy, the fetus and its lungs were weighed and the LBWR was calculated.  186 
Histology and semi-automatic quantification  187 
Paraffin blocks were cut in 4-µm sections displaying the area of the defect. Staining with hematoxylin 188 
and eosin (H&E) was performed and an average score from 3 high power fields per slide (x40 189 
magnification) around the defect was calculated for polymorphonuclear cell (PMN) infiltration as 190 
previously described 
15
. Immunohistochemistry (IHC) for Ki67, Vimentin and Cytokeratin was 191 
performed according to standard IHC protocols as described before 
16
. TUNEL staining (In Situ Cell 192 
Death Detection Kit, Fluorescein; Roche Diagnostics GmbH, Mannheim, Germany), detecting 193 
apoptotic cells, was performed according to the producer’s recommendations with DAPI as a 194 
background staining. Ki67 was quantified to assess cell proliferation. The presence of EMT was 195 
investigated by an IHC vimentin/cytokeratin ratio. 196 
IHC and TUNEL positive cell density measurements were performed semi-automatically, using ImageJ 197 
software (v1.48, NIH, USA). From each slide, 3 random non-overlapping images were recorded 198 
(Axioskop; Carl Zeiss) at ×40 magnification at the contact-area between sealant and tissue. An 199 
average density was calculated for each slide and presented as mean ± standard deviation (SD). The 200 
digital color images were segmented, and Ki67, Vimentin and Cytokeratin staining was quantified. 201 
The total number of cells as well as the amount of positively stained cells was determined, and the 202 
density was expressed as a percentage (positive cell area/total area of cells). TUNEL staining was 203 
expressed as a percentage of TUNEL positive cells/ DAPI positive cells. 204 
Statistics  205 
Statistical analysis was performed with SPSS® Statistics software v21.0. (IBM®, Company). A p-value 206 
of <0.05 was considered significant. Continuous variables were tested for normal distribution by 207 
Kolmogorov-Smirnov test and expressed as mean and standard deviation (SD). Binomial and ordinal 208 
variables were expressed as percentage and score, respectively. One-way ANOVA with Tukey post-209 
hoc analysis was used to compare normally distributed continuous variables and Kruskal-Wallis test 210 
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for non-normally distributed continuous variables. Chi-square test was used for binomial and ordinal 211 
variables. The investigational groups were compared to the negative controls. Positive controls were 212 
used as reference, if no negative control group was included in the outcome. Lyostypt® was used as 213 
reference for surgical handling readouts (Supplementary Table 1). Statistical results are represented 214 
in APA (American Psychological Association) style. Power calculation was performed with StatMate 215 
v2.0 (GraphPad, San Diego, California, USA) according to the published literature 
4
, we calculated that 216 
a sample size of 9 fetuses/group would provide a power of ≥85% with a 5% two-sided type I error to 217 
detect a 20% difference in fetal survival. 218 
219 
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Results 220 
 221 
A total of 35 does and 332 fetuses were included in the study. There were 231 unmanipulated 222 
control fetuses, 18 in the Lyostypt® group, 14 in the condensed collagen group, 25 in the collagen + 223 
fibrinogen group, 13 in the Tissuepatch® group, 15 in the Duraseal® group and 16 in the unsealed 224 
positive control group. 225 
Overall, fetal survival in unsealed sacs tended to be lower (75%) than in unmanipulated control sacs 226 
(91%), yet that did not reach statistical significance (
=3,478; p=0,082, Table 1). Two sealants had 227 
no effect on fetal survival when compared to unmanipulated control sacs: Condensed collagen 228 
(11/14, 78%; 
=1,831; p=0,175) and Tissuepatch® 10/13, 77%; 
=2,225; p=0,149). Sealing with 229 
three of the used strategies was associated with a reduced fetal survival compared to negative 230 
controls, i.e. Lyostypt® (13/18, 72%; 
=5,314; p=0,038), collagen + fibrinogen (12/25, 48%; 231 

=32,996; p<0,001) and Duraseal® (9/15, 60%; 
=12,226; p=0,004, Table 1). However, in sacs of 232 
surviving fetuses from these three sealant groups, there was no difference with positive controls in 233 
terms of inflammation (number of PMN) (	
 =13,067; p=0,364), or TUNEL positive cells (F=2,135; 234 
p=0,056) (Figure 2 and Table 1).  235 
Pregnancies sealed using condensed collagen and Tissuepatch® underwent further efficacy testing. 236 
Tissuepatch® sealed sacs had a DVP comparable to that of normal controls (4,64 ± 2,24 vs 6,93 ±3,80) 237 
but condensed collagen sealed sacs had a significantly lower DVP at harvesting (1,89 ± 1,30; F=8,638; 238 
p<0,001). There was a 10% amniotic fluid leakage rate (n=1/10) in the Tissuepatch® group which was 239 
significantly less than the condensed collagen group (n=6/11) and the positive controls (n=6/12; 240 
	
=4,023; p=0,045). It was also easier to insert Tissuepatch® than the condensed collagen plug with 241 
less problems at plug insertion (	
 =179,535; p<0,001). There was no difference in macroscopic 242 
persistence of the sealing materials used (	
=11,399; p=0,44239). Remarkably, there were no 243 
differences in LBWR between any of the four groups (F=1,417; p=0,213). The degree of cell 244 
proliferation (Ki67), was higher in the Tissuepatch® group than in negative controls (3,03, ± 1,81 245 
versus 1,23 ± 0,72; F=4,575; p<0,001). There was no difference in the proportion of cells staining for 246 
vimentin or cytokeratin (EMT) between the treatment groups, positive or negative controls (F=1,804; 247 
p=0,106) (Figure 3 and Table 1). Single electron microscopy (SEM) images were taken from the 248 
Lyostypt® and condensed collagen plugs to compare the structure of the two sealants and revealed a 249 
smaller diameter, higher density and better alignment of collagen fibers in the condensed collagen 250 
(Supplementary Figure 2).  251 
  252 
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Discussion 253 
 254 
Herein we compared 4 new techniques to seal iatrogenic fetal membrane defects in a fetoscopy 255 
rabbit model in terms of biocompatibility and efficacy with a previously used technique of Lyostypt®. 256 
Three of the sealants were associated with a higher rate of fetal demise compared to non-operated 257 
control pregnancies. Tissuepatch® and condensed collagen were the only sealants that had similar 258 
results to non-operated controls in the primary outcome variable of fetal survival, but Tissuepatch® 259 
proved easier to manipulate surgically and induced limited cell proliferation. 260 
We first screened candidate sealants for the most direct adverse effect, i.e. fetal death. In the group 261 
of products initially screened yet later disqualified, the fetal death rate ranged from 28 to 52%, 262 
versus a death rate of around 25% in positive controls. The latter loss rate is in line with previous 263 
studies, confirming reproducibility of the model 
4,16
. At the same time, it indicates a frailty of the 264 
model due to anesthesia and manipulation of the uterus and its contents. The increased death rate in 265 
three of the sealant treatment groups would therefore suggest an additional factor besides 266 
fetoscopy as potential cause of death. Histological examination did not demonstrate any increased 267 
apoptosis or infiltration of polymorphonuclear cells in the membranes of these three sealant groups. 268 
With the current design, we were unable to investigate precisely the cause and timing of fetal death 269 
as there was only one time point of fetal viability evaluation, to limit repeated anaesthesia in the 270 
does. In the collagen + fibrinogen group there was a higher (>50%) death rate, yet no obvious factor 271 
explaining that excess could be identified. Potential explanations are local fibrin formation, when 272 
fibrinogen gets in contact with the amniotic fluid. Such increased mortality was already described in 273 
earlier experiments, where fibrin glue was used 
18
. The exact mechanism behind that remains 274 
unclear. The fetal survival in the Duraseal® group was also lower. Again, we did not find a direct 275 
explanation on necropsy or histology in that group. Potentially it ties to the injectabl  nature of the 276 
product or its expanding nature 
19
. During injection components of the glue can freely and 277 
excessively enter the amniotic cavity and may have direct effects on the fetus.  278 
We then moved into further experimentation with Tissuepatch® and condensed collagen, to study 279 
efficacy. Condensed collagen plug created unfortunate problems at surgical plug insertion despite its 280 
good biocompatibility. Problems associated with insertion of the condensed collagen plug included 281 
structural break down of the plug during surgical manipulation and difficulties at suturing, which 282 
influenced further readouts. Tissuepatch® sealed sacs had a DVP in the normal range and obvious 283 
leakage rate was low, within the range of intact sacs of unmanipulated controls. Macroscopically the 284 
plug seemed well locked to the sealing site by sutures. On histological examination, we did not see 285 
direct evidence of integration and / or healing response despite an elevated proportion of Ki67 286 
positive cells in the Tissuepatch group compared to negative controls. During the fixation of the 287 
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sealing site in PFA, Tissuepatch® dissolves partly, making it impossible to trace the initial borders and 288 
integrity of the plug. Indirectly however, there was no evidence for much interaction between the 289 
plug and the sealing product, as we did not see an increase in proliferation, signs of inflammation nor 290 
apoptotic effect around the sealing site. It is therefore not impossible that the effect of this product 291 
being sutured into a fetoscopic defect, was merely mechanical plugging, yet without causing direct 292 
local inflammatory or fetal side effects. Assuming the efficacy of Tissuepatch®, one could speculate 293 
on how this would be clinically translated. This would obviously be an off-label use, yet it is an FDA 294 
approved product for visceral pleura sealing. The patch has a self-adhesive visceral side, yet we could 295 
not take advantage of this in this model and still needed to fix the patch as the adhesive properties in 296 
under water conditions are not documented. A more intuitive clinical application would be to use 297 
this patch in open fetal surgeries where suturing to the amnion would be feasible.  298 
This study has some limitations, particularly when comparing the rabbit model of fetal membrane 299 
sealing with human pregnancy. The myometrial thickness and contractility as well as the resealing 300 
capabilities of the rabbit amnion are different from those in women 
20
. Also, there is the difference of 301 
the application method one can use in this animal model and what would be possible in the clinical 302 
situation. The size difference of the defect makes surgical applications of sealants more difficult 303 
compared to the clinical situation. In clinical fetoscopy it is also not possible to place a sealant on the 304 
chorionic side of the amnion, which is possible in the rabbit model as amnion, chorion and uterine 305 
wall are not attached to each other. Also in this experiment, there was a clear relationship between 306 
difficulties handling properties and later efficacy. So, it is possible that we underestimate efficacy of 307 
certain methods because they are difficult to insert in a rabbit. As the application technique itself 308 
was not a focus of our study, one would need to investigate products in another model that is better 309 
simulating clinical circumstances. The choice for some readouts may also need to be questioned. For 310 
instance, we assessed EMT, because it was earlier named to be relevant in human amnion samples 311 
from clinical fetoscopies 
21
. EMT is a key-component of wound healing, and we speculated that it 312 
would point to local regeneration. Herein we could not demonstrate any change in EMT between any 313 
of the groups, questioning it as an outcome measure in this model. In retrospect, we could have 314 
included other readouts such as fetal systemic inflammation to understand adverse effects more 315 
effectively, or could have followed up on fetuses postoperatively to determine the GA at intra-316 
uterine fetal death. This study also involved several subjective outcome measures. No matter how 317 
much we tried to make our readouts as objective as possible, they are not free of a certain amount of 318 
operator bias. Lastly, some of our observations were not in line with other studies using the same 319 
model. For instance we did not find a decrease of LBWR due to the decreased amniotic fluid 
22
.  320 Formatted: English (U.S.)
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On the other hand, our study had strengths, we observed that many other outcomes were similar to 321 
what was demonstrated earlier (survival rate, outcomes in positive and negative controls, and the 322 
amniotic fluid). This would suggest that findings in the rabbit model are reproducible. Also, we 323 
explored several methods, many of them clinically conceivable. The numbers of animals used are 324 
high compared to previous studies and our study was adequately powered. The microscopic 325 
readouts were done semi-automatically.  326 
In summary, this study provides experimental evidence that Tissuepatch® has the best combination 327 
of biocompatibility, surgical ease and efficacy in sealing an iatrogenic fetal membrane defect in the 328 
pregnant rabbit compared to other sealants. However, the current formulation of Tissuepatch® is not 329 
easy to insert fetoscopically in an effective way. Therefore, our quest into an effective and clinically 330 
usable and approved sealing technique is ongoing.  331 
  332 
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Figure legend 404 
Figure 1: Photographs of the surgical procedure. (A) Opening of the myometrium and chorion. View 405 
on amnion before puncturing. (B) Fetoscopic view of fetal front limb. (C) Insertion of a collagen plug 406 
while withdrawing the cannula. (D) Closure of the myometrium. 407 
Figure 2: Results of TUNEL staining displayed along with two microscopic images of TUNEL stainings 408 
at x40 magnification. DAPI was used as background staining (blue). 409 
Figure 3: Graphical results of the efficacy testing. Results of the second part of the study that were 410 
retrieved as percentage are displayed in table 1. 411 
 412 
Table legend 413 
Table 1: Results for each variable and each sealant are given including the significance level. Results 414 
are presented as percentages or as mean with standard deviation (SD) where appropriate. P-values 415 
were calculated by cross-tables including all groups. PMN = polymorphonuclear cell infiltration. 416 
 417 
Supplementary 418 
Supplementary Figure 1: Workflow of the study.  419 
Supplementary Figure 2: Comparison of condensed collagen vs Lyostypt® by single electron 420 
microscopy (SEM) shows a a smaller diameter, higher density and better alignment of collagen fibers 421 
in the condensed collagen compared to Lyostypt®.. 422 
Supplementary Video 1: Video of rabbit fetoscopy.  423 
Supplementary Table 1: Statistical tests with normal distribution and used reference group for all 424 
readouts. 425 
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 Figure 1: Photographs of the surgical procedure. (A) Opening of the myometrium and chorion. View 317 
 on amnion before puncturing. (B) Fetoscopic view of fetal front limb. (C) Insertion of a collagen plug 318 
while withdrawing the cannula. (D) Closure of the myometrium.  
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 Figure 2: Results of TUNEL staining displayed along with two microscopic images of TUNEL stainings 320 
at x40 magnification. DAPI was used as background staining (blue).  
 
150x126mm (300 x 300 DPI)  
 
 
Page 18 of 21
http://mc.manuscriptcentral.com/pd
Prenatal Diagnosis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
 Figure 3: Graphical results of the efficacy testing. Results of the second part of the study that were 322 
retrieved as percentage are displayed in table 1.  
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Part 1: Biocompatibility: 
 
Part 2: Efficacy: 
Readout Neg 
controls 
Condensed 
collagen 
Tissuepatch Pos controls P-value 
DVP (mm) 6,93 (±3,80) 1,89 (±1,30)* 4,68 (±2,24) 1,60 (±1,73)* <0,001 
Fluid leakage 
(%) 
- 6/11 (55%) 1/10 (10%)* 6/12 (50%) <0,001 
Problems at 
plug insertion 
(%) 
- 5/11 (45%)* 1/10 (10%) - <0,001 
Persistence 
of plug (%) 
- 7/11 (64%) 9/10 (90%) - 0,449 
LBWR (ratio) 0,025 ± 
0,003 
0,022 ± 0,002 0,023 ± 0,002 0,023± 0,003 0,213 
Ki67 (%) 1,23 
(±0,722) 
2,00 (±1,274) 3,03 
(±1,805)* 
2,70 (±1,609) <0,001 
Vim/Cyt 
(ratio) 
1,00 
(±0,536) 
0,97 (±0,512) 1,33 (±0,568) 1,38 (±0,579) 0,106 
Readout Neg controls Lyostypt Condensed 
collagen 
Coll+Fibr Tissuepatch Duraseal Pos controls P-value 
Fetal survival 
(%) 
208/231(91%) 13/18 (72%)* 11/14 (78%) 12/25 (48%)* 10/13 (77%) 9/15 (60%)* 12/16 (75%) <0,001 
PMNs (mean 
score) 
0,73 (±0,458) 1,00 (±0,378) 0,80 (±0,414) 1,00 (±0,535) 0,80 (±0,414) 1,13 (±0,352) 0,87 (±0,352) 0,364 
TUNEL (%) 2,01 (±1,03) 3,67 (±1,67) 2,61 (±1,39) 3,93 (±2,56) 2,81 (±1,56) 3,53 (±2,27) 2,66 (±1,87) 0,056 
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